What is Opt2Pay?
Opt2Pay enables authors to pre-pay to make the final authoritative version of their journal articles freely available immediately upon publication, on payment of a licence fee.
When will I be given the option to pre-pay for making my article freely available online?
You will be asked to indicate whether you would like to opt to pay for providing access to your article online when your paper is accepted for publication.
You will be asked to sign an appropriate licence as part of the submission process, which will explain that the Version of Record (VoR)∗ of your article will only be made freely available once payment has been processed, with a default to the exclusive licence to publish if payment is not forthcoming.
Upon acceptance, you will be prompted to complete an additional Opt2Pay charge form.
The processing of your article will not be delayed in any way or at any stage owing to a failure to pay; however, the Version of Record (VoR) will not be made freely available until payment has been processed, but it will be available via the reader-pays option under the exclusive licence to publish.
The Immediate Publication (IMP) of your article (= Accepted Manuscript, AM)∗ will appear on the journal website, typically on the day that it is accepted, regardless of which publishing model you choose.
Will the payment of a fee have any influence on whether my article is accepted for publication?
All manuscripts submitted to journals published by Portland Press Limited will receive the same fair, thorough and fast peer-review process. The Journal's Editors will not know whether an author has opted to pre-pay for access. You will only be asked to indicate whether you wish to opt to pay when your manuscript is accepted for publication.
How much will I have to pay?
For corresponding authors from organizations that hold a current online or combined subscription at the time that their manuscripts have been accepted for publication the fee for this option is £1500; US$3000; €2200.
For an author based at an organization that does not have a current subscription the fee is: £1750; US$3500; €2590.
Is this the true cost of publishing my article?
No, this is currently being heavily subsidized by the traditional reader-pays (subscription) model. As more authors opt to pre-pay for their articles, the pre-payment fee is likely to increase to enable us to recover our costs, make a surplus for future investment, and to allow the Biochemical Society to continue to provide support for the research community. There will be a concomitant decrease in the subscription as the amount of freely accessible content increases significantly.
Will I have to pay a submission fee?
Are there any additional page charges?
Will I still have to pay for colour?
The above optional pre-payment charges are in addition to any colour charges that might apply.
Will I get a discount if my organization has a current subscription?
Yes, if your organization has an active subscription.
How can I find out if my institution has a current combined or online-only subscription?
You can use the following links to confirm if your institution subscribes to a particular title (you must be at the subscribing institution to use these links):
Will an institutional print subscription
entitle me to the discounted fee?
- Biochemical Journal – http://www.portlandpress.com/ppl/subs_sirius.asp?jnl=BJ
- Biochemical Society Transactions – http://www.portlandpress.com/ppl/subs_sirius.asp?jnl=BST
- Clinical Science – http://www.portlandpress.com/ppl/subs_sirius.asp?jnl=CLI
No, only a current online only or combined subscription will entitle you to the discount.
Will I get a discount if I am a member of the Biochemical Society?
Yes, if the corresponding author has been a Full or Early Career member of the Society for at least 2 years.
What if I cannot pay?
If you cannot afford to pre-pay for access, your article will be available via the reader-pays (subscription) model.
Will publication of my manuscript be delayed if payment is not received by the time it is accepted for publication?
Portland Press Limited
constantly endeavours to keep handling times to the minimum. The processing of your article will not be delayed in any way at any stage owing to a failure to pay; however, the Version of Record (VoR) of your accepted article will not be made freely available until payment has been processed, but it will be available via the reader-pays (subscription) option.
How will readers know which articles have pre-paid access?
Such articles will be clearly identifiable via the Opt2Pay icon in the Table of Contents and on the article itself.
How will Opt2Pay affect my copyright?
Articles of authors who opt to pre-pay for access will be made available under the Creative Commons Attribution Licence (CC-BY), which permits unrestricted use, distribution and reproduction in any medium, provided the work is cited appropriately.
How may authors use Opt2Pay articles?
The Opt2Pay scheme entitles you and your co-authors to post the PDF version of your Version of Record (VoR), for non-commercial purposes, on your own or institutional website, or to free public servers in the relevant subject area, in whole or in part according to the terms of the licence. This is provided you include a link to the published version of the article on theappropriate Journal website and that the Journal, the Biochemical Society and Portland Press are given the correct attributions.
Portland Press Limited will undertake to post all pre-paid articles to PubMed Central, as a service to its authors on receipt of payment, and permit their inclusion in PubMed Central mirror sites. You will be notified of the PMCID for your article by email.
What happens to my copyright if I do not pre-pay for free access?
Portland Press Limited and the Biochemical Society do not require authors who opt not to pay to transfer their copyright, but do require the grant of an exclusive licence to publish. The copyright in the article will remain with the author(s), and Portland Press Limited will acknowledge this in the copyright line which appears on the article.
All authors are free to use their Accepted Manuscript (AM) for self-archiving on their own website or in their institutional repository, after 6 months, provided it is made clear that this is not the Version of Record (VoR), and that a link is provided to the Version of Record (VoR) on the Journal website and that the Journal, the Biochemical Society and Portland Press are given the correct attributions.
Portland Press Limited Journals are compliant with the NIH mandate: authors may deposit their Accepted Manuscript (AM) in PubMed Central immediately on acceptance with an embargo for public release of 12 months from the date of print publication.
What about authors from developing countries?
Portland Press supports HINARI run by the World Health Organization and part of the Research4Life partnership. This means that low-income countries can already obtain free (or very low-cost) access to its journals.
Access and further information is available at www.who.int/hinari or email firstname.lastname@example.org
Will there be any pricing adjustments for subscribing libraries as a result of Opt2Pay?
Any increases in subscription prices to our journals take into account other sources of income to the journal, including Opt2Pay, and price increases are moderated wherever possible.
∗For definitions of journal article versions, see the Recommended Practice of the National Information Standards Organization in Partnership with the Association of Learned and Professional Society Publishers.
Portland Customer Services
Charles Darwin House
12 Roger Street
Tel: +44 (0)20 7685 2444
Fax: +44 (0)20 7685 2468
Portland Press Ltd.
Charles Darwin House
12 Roger Street
London WC1N 2JL
Tel: +44(0) 20 7280 4110
Fax: +44(0) 20 7280 4169